Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Exelixis Expands Cabometyx Row But Faces ‘Patent Thicket’ Claim

Sept. 6, 2022, 8:32 PM

Exelixis Inc. expanded its courtroom offensive protecting its cancer drug Cabometyx, alleging in a new lawsuit that Teva Pharmaceutical Industries Ltd.’s proposed copy infringes another patent for the blockbuster pharmaceutical, even as Exelixis faces a different generic-drug maker’s accusation that it improperly acquired three crucial Cabometyx patents in pursuit of a “thicket.”

Exelixis seeks an order blocking the effective date of any US Food and Drug Administration approval of Teva’s copy until the patent expires in February 2032, according to a complaint filed Sept. 2 in the US District Court for the District of Delaware.

That’s more than eight years ...